Article ID Journal Published Year Pages File Type
5655407 Digestive and Liver Disease 2016 6 Pages PDF
Abstract
FOLFOX4 chemotherapy is likely to be a cost-effective option compared with sorafenib in the treatment of advanced hepatocellular carcinoma in China.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism
Preview
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis
Authors
, , ,